share_log

FOXO TECHNOLOGIES INC. ANNOUNCES THAT STOCKHOLDERS EQUITY IS GREATER THAN $4M, WHICH IS REQUIRED TO MEET THE CONTINUED LISTING REQUIREMENTS OF THE NYSE AMERICAN EXCHANGE

FOXO TECHNOLOGIES INC. ANNOUNCES THAT STOCKHOLDERS EQUITY IS GREATER THAN $4M, WHICH IS REQUIRED TO MEET THE CONTINUED LISTING REQUIREMENTS OF THE NYSE AMERICAN EXCHANGE

FOXO TECHNOLOGIES INC. 宣佈股東權益超過400萬美元,這符合美國交易所紐交所的持續上市要求。
GlobeNewswire ·  12/17 01:32

MINNEAPOLIS, MN, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO") announces that recent transactions have led to the Company having stockholders equity greater than $4M and, as a result, it has regained compliance with NYSE American continued listing requirements for stockholders equity.

明尼阿波利斯,MN,2024年12月16日(環球新聞網絡)-- FOXO科技公司(紐交所美國:FOXO)(以下簡稱「公司」或「FOXO」)宣佈,最近的交易使得公司的股東權益超過400萬美元,因此,它已重新符合紐交所美國對股東權益的持續上市要求。

As was disclosed in the Company's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on November 19, 2024, the Company had a stockholders' deficit of approximately $17.5 million in its unaudited financial statements as of September 30, 2024. Since then, the Company has been working to secure agreements from certain creditors, debt holders, and investors to exchange their debt to equity in the form of Preferred Stock which would be treated as equity.

正如公司於2024年11月19日提交給美國證券交易委員會(「SEC」)的10-Q季度報告中披露的,截止到2024年9月30日,公司在未經審計的基本報表中顯示出約1750萬的股東赤字。自那以來,公司一直在努力與某些債權人、債務持有人和投資者達成一致,以將其債務以優先股的形式轉換爲股權。

The Company was successful in securing:

公司成功達成了:

  • Rennova Health, Inc.'s exchange of $21 million of the Company's Senior Secured Note issued by Rennova Community Health, Inc. (the Company's wholly owned subsidiary) into 21,000 shares of the Company's Series A Cumulative Convertible Redeemable Preferred Stock ("Series A Preferred Stock")
  • An institutional investor's additional funding of $1.0 million and exchange of approximately $2.2 million of Senior Notes (including the newly issued approximately $1.0 million) into 2,464 shares of the Company's Series A Preferred Stock
  • Settlement of certain liabilities owed to KR8 AI, Inc., and the termination of a license agreement in exchange for 3,000 shares of the Company's newly designated Series D Cumulative Convertible Redeemable Preferred Stock
  • Additionally, the Company had approximately $1.0 million of other liabilities and notes converted to approximately 2 million shares of Class A Common Stock since October 1, 2024
  • Rennova Health, Inc. 將2100萬公司的高級擔保票據轉換爲21,000股公司的A系列可累積可轉換可贖回優先股("A系列優先股")
  • 一名機構投資者提供的額外融資100萬,並將約220萬的高級票據(包括新發行的約100萬)轉換爲2,464股公司的A系列優先股
  • 結清對KR8人工智能公司的某些負債,以及在交換3000股公司新指定的D系列可累積可轉換可贖回優先股的情況下終止一項許可協議
  • 此外,自2024年10月1日以來,公司有約100萬的其他負債和票據轉換爲約200萬股A類普通股

"I am delighted we can inform our shareholders that stockholder's equity is now greater than $4 million," said Seamus Lagan, the Company's Chief Executive Officer. "We believe this eliminates the risk of delisting from NYSE American for a stockholders equity deficiency that has hung over the Company for the past 18 months. We are committed to continued growth and improvements for the benefit of our shareholders in the coming years," continued Mr. Lagan.

「我很高興能通知我們的股東,股東權益現在超過400萬,」公司首席執行官Seamus Lagan說。「我們相信這消除了由於股東權益不足而導致的從紐約證券交易所美國退市的風險,這種風險困擾了公司長達18個月。我們致力於在未來幾年繼續爲我們的股東帶來增長和改善,」Lagan先生繼續說道。

The Company filed a Current Report on Form 8-K with the SEC on December 10, 2024, which provides additional details on the above transactions and related Company actions and activities. If at any time in the future the Company falls out of compliance with the stockholders equity requirements to meet NYSE American continued listing rules, the Company would be subject to immediate reevaluation by NYSE American.

公司於2024年12月10日向證監會提交了8-K表格的當前報告,提供了有關上述交易及相關公司行動和活動的更多細節。如果未來公司不再符合滿足紐交所美國掛牌續存規則的股東權益要求,公司將面臨紐交所美國的即時重新評估。

About FOXO Technologies Inc. ("FOXO")

關於FOXO科技公司("FOXO")

FOXO owns and operates three subsidiaries.

FOXO擁有並運營三家子公司。

Foxo Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.

Foxo Labs, Inc.是一家生物技術公司,致力於通過開發前沿科技和產品解決方案來改善人類健康和壽命,面向各個行業。

Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services.

Myrtle Recovery Centers, Inc.是一家位於東田納西州的30牀位的行爲健康設施。Myrtle提供戒毒和住院治療的住院服務以及門診服務。

Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical), a critical access designated (CAH) hospital in East Tennessee.

Rennova社區醫療公司擁有並運營斯科特縣社區醫院(商業名稱:大南叉醫療),這是一家位於東田納西州的關鍵接入指定醫院。

For more information about FOXO, visit .

有關FOXO的更多信息,請訪問 .

Forward-Looking Statements [BH should review and clean-up for next time]

前瞻性聲明 [BH 應該爲下次審核並清理該內容]

This press release contains certain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements about trading of the Warrants in the over-the-counter market, the continued listing of the Company's Class A common stock on NYSE American, and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning, but the absence of these words does not mean that a statement is not forward-looking. Any such forward-looking statements are based upon the current beliefs and expectations of the Company's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond the Company's control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the possibility that the Plan will not be accepted by NYSE American, the Company will be unable to satisfy other continued listing requirements of NYSE American for its Class A common stock to maintain the listing of the Class A common stock on NYSE American; the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO's business; the ability to implement FOXO's business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans; the enforceability of FOXO's intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO's most recent reports on Forms 10-K and 10-Q, particularly the "Risk Factors" sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

本新聞稿包含某些前瞻性聲明,以符合1995年《美國私人證券訴訟改革法》的「安全港」條款。除歷史事實外,本文所包含的任何聲明,包括關於 Warrants 在場外市場交易的聲明、公司A類普通股在紐約證券交易所(NYSE American)持續上市的聲明以及其他以「可能導致」、「預計將」、「將繼續」、「預計」、「估計」、「相信」、「打算」、「計劃」、「預測」、「前景」或類似含義的詞語標識的聲明,但這些詞語的缺失並不意味着該聲明不是前瞻性聲明。任何此類前瞻性聲明均基於公司管理層當前的信念和預期,且固有地面臨着重大業務、經濟和競爭不確定性及意外情況,其中許多是難以預測的,通常超出公司控制範圍。許多因素可能導致實際未來事件與本新聞稿中的前瞻性聲明存在重大差異,包括但不限於該計劃未被紐約證券交易所(NYSE American)接受的可能性,公司將無法滿足A類普通股在紐約證券交易所(NYSE American)保持上市的其他持續上市要求;在FOXO所經營的競爭激烈且高度監管行業中的變化風險;不同競爭對手間的運營表現差異或影響FOXO業務的法律法規變化;實施FOXO的業務計劃、預測和其他期望的能力;獲得融資的能力;FOXO 有過虧損歷史並可能無法在未來實現或維持盈利的風險;FOXO 在推進其目標或實現商業化和發展計劃時可能無法建立或維護所需的關係;FOXO的知識產權的可執行性,包括其專利和對他人知識產權的潛在侵害;以及在 FOXO 所經營的生物技術行業或相關市場或行業中,經濟下滑和監管環境變化的風險。上述因素列表並不詳盡。讀者應仔細考慮上述因素及在 FOXO 最近的10-K和10-Q表格報告中討論的其他風險和不確定性,特別是這些報告的「風險因素」部分,以及FOXO提交或將提交給證券交易委員會(SEC)的其他文件。這些文件識別和處理可能導致實際事件和結果與前瞻性聲明中所包含內容存在重大差異的其他重要風險和不確定性。前瞻性聲明僅在作出聲明的日期有效。讀者應警惕不要對前瞻性聲明給予過度信任,FOXO 不承擔任何義務,也不打算更新或修訂這些前瞻性聲明,無論是由於新信息、未來事件,還是其他原因。

Contact:
Crescendo Communications, LLC
(212) 671-1020
foxo@crescendo-ir.com

聯繫:
Crescendo Communications, LLC
(212) 671-1020
foxo@crescendo-ir.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論